Publications
148
Citations
10,396
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
This publication record appears to combine work from multiple researchers sharing the name Wei Lang, spanning myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) molecular biology, vaccine clinical trials, gastric cancer surgery outcomes, and obesity/physical activity research. The MDS/AML-focused work investigates genetic and molecular mechanisms (such as gene mutations, chromosomal abnormalities, and single-cell profiling) that drive disease progression and prognosis, while other threads examine vaccine safety in clinical trials and behavioral or surgical interventions for chronic disease. Because the topics are so disparate, prospective students should verify which specific research group and institution this profile refers to before assuming a single coherent research program.
Publication output has fluctuated over the last decade, with lower counts around 2018-2021, a peak in 2022, and renewed activity in 2024, averaging about 6.4 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Exploring LEO Satellite Networks for Continuous Monitoring and Dynamic Tracking
2026
- Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
The Lancet Microbe · 2025
- EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes
Experimental Hematology and Oncology · 2025
- The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes
Journal of Translational Medicine · 2025
- 596. Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated With and Without Tdap in Healthy Children 6 to 17 Years Old: A Phase 2b, Randomized, Active-Controlled Study
Open Forum Infectious Diseases · 2025
- Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes
Blood · 2025
- RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Science Advances · 2024
- Can proximal gastrectomy with double-tract reconstruction replace total gastrectomy? a meta-analysis of randomized controlled trials and propensity score-matched studies
BMC Gastroenterology · 2024
- The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms
Leukemia · 2024
- Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes
Journal of Clinical Investigation · 2024
- Mesocolic schwannoma mimicking gastrointestinal stromal tumor: A case report and review of literature
Medicine · 2024
- The der(1;7)(q10;p10) defining a distinct profile from −7/del(7q) in myelodysplastic syndromes: A systematic review and meta‐analysis
Cancer Medicine · 2024
- HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment
Blood · 2024
- Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes
Blood · 2024
- Trends and Attributable Risk Factors of the Global Burden of Lymphoid Malignancies over the Past Fifteen Years
Blood · 2024
- Blood×7
- Obesity×5
- Health Psychology×3
- Experimental Hematology and Oncology×2
- Hematological Oncology×2
- Karla I. Galavíz
Medicine · Indiana University
- NiCole R. Keith
Medicine · Indiana University
- Justin Richards
Medicine · The Ohio State University
- Brooke E. Starkoff
Medicine · The Ohio State University
- Rick Petosa
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile